Journal of Clinical Oncology
Articles in this Issue
Inotuzumab ozogamicin versus blinatumomab in pediatric relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.
e18512 Background: Inotuzumab ozogamicin (InO, CD22-directed) and blinatumomab (blina, CD19-directed) are increasingly use...
Long-term outcomes of <sup>18</sup> F-fluoromisonidazole positron emission tomography (FMISO PET)–guided major radiation dose de-escalation in HPV-associated oropharyngeal cancer: The 30 ROC approach.
103 Background: We previously demonstrated favorable short-term outcomes in patients with human papillomavirus–associated...
First-in-human phase 1/2 study of ETX-19477, an oral, potent, and selective PARG inhibitor, in patients with advanced solid tumors (ERADIC8).
3109 Background: Poly(ADP-ribose) glycohydrolase (PARG) is an enzyme that catalyzes the removal of poly-ADP-ribose (PAR) c...
Bone marrow vascular architecture: Implications for targeting bone marrow cancers.
e18610 Background: Many hematologic cancers (HC) are localized in the bone marrow (BM). Drug therapies are often administe...
Cancer treatment: Impact on metabolism.
e24140 Background: It is well-accepted that metabolic syndrome can drive cancer development through changes in insulin sig...
The hidden struggle? Mental health burden among oncology physicians globally.
9012 Background: Oncology physicians face demanding clinical workloads, high emotional labor, and frequent exposure to pat...
A randomized, double-blind, placebo-controlled trial of antiviral prophylaxis and oral <i>Herpesviridae</i> dynamics during radiotherapy for head and neck cancer.
TPS12163 Background: Oral mucositis (OM) is a frequent and debilitating toxicity of radiotherapy (RT) for head and neck ca...
Pilot study of whole-exome sequencing and single-nucleus RNA sequencing to identify actionable alterations in cancer.
e15078 Background: DNA sequencing employing comprehensive genomic profiling (CGP) or whole-exome sequencing (WES) is widel...
Time-dependent patterns of immune-related adverse events by obesity status following immune checkpoint inhibitor therapy: A real-world cohort analysis.
11191 Background: Immune checkpoint inhibitors (ICIs) substantially improve cancer outcomes but are frequently complicated...
Addressing housing instability as a quality-of-care determinant in cancer: A meta-analysis across national and Veterans Affairs cohorts.
11045 Background: Housing instability is an under-recognized determinant of cancer outcomes that directly affects screenin...
Clinicopathologic and genomic landscape of pancreatic acinar cell carcinoma: A single-center experience.
e16484 Background: Pancreatic acinar cell carcinoma (PACC) is an ultra-rare (~1%) pancreatic malignancy. Management is oft...
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.
4010 Background: In HERIZON-GEA-01 (NCT05152147), 1L zanidatamab + CT ± tislelizumab significantly improved progression-fr...
SOHO-01: Updated safety and efficacy of sevabertinib in patients with advanced <i>HER2</i> -mutant non-small cell lung cancer (NSCLC).
8622 Background: Sevabertinib, a potent, reversible, oral tyrosine kinase inhibitor, received FDA accelerated approval for...
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor–naïve patients with metastatic uveal melanoma.
TPS9598 Background: Uveal melanoma (UM) is the most common primary intraocular malignancy, accounting for ~90% of ocular m...
Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer.
8645 Background: Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer-related deaths, with MET...
Evaluation of <i>KRAS</i> -mutant circulating tumor DNA as a surgical biomarker in localized pancreatic cancer treated with multi-agent neoadjuvant chemotherapy.
e16471 Background: Circulating tumor DNA (ctDNA) is a promising biomarker for risk stratification in localized pancreatic...
Lumbar puncture in thrombocytopenic adults with leukemia and lymphoma revisited: A scoping review.
e18612 Background: Patients with hematological malignancies may require a lumbar puncture (LP) for evaluation of central n...
Smoking prevalence as a predictor of preventable cancer burden: A mediation analysis with health systems performance in 167 nations (2008–2023).
e22678 Background: Smoking prevalence and cancer mortality relationships vary significantly across healthcare systems. Hea...
Association of cardiovascular toxicities with bispecific antibody therapy in patients with hematologic malignancies: A single-center retrospective analysis.
e19014 Background: Bispecific antibodies (bsAbs) are an emerging treatment for hematologic malignancies, but data on cardi...
Clinical outcomes for low-income patients with early-onset colorectal cancer: An analysis of the National Inpatient Sample.
e15697 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset colorectal ca...
ProTACT: Preliminary data from a first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [ <sup>225</sup> Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
5050 Background: [ 225 Ac]Ac-FL-020 is a next-generation, prostate-specific membra...
First-line induction oxaliplatin-based chemotherapy followed by maintenance in isolated peritoneal metastatic colorectal cancer: Real-world outcomes from Vietnam.
e15524 Background: Isolated peritoneal metastatic colorectal cancer (IPM-CRC) represents a rare and biologically unique en...
IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).
4002 Background: Several immuno-oncology therapies are available for 1L HCC, but data are limited after progression. IMbra...
Platinum rechallenge versus non-platinum regimens as second-line treatment for advanced thymoma: Analysis of the largest retrospective cohort to date.
8117 Background: Although guidelines list platinum-based combination chemotherapy (Pt-rechallenge) as a second-line strate...
Oral mannitol for chemotherapy-induced constipation (CIC): A randomized, multicenter, controlled study.
12146 Background: Chemotherapy-induced constipation (CIC) is a common yet frequently overlooked supportive care issue, cur...